These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 2096913)
1. Immunoconjugate design: a predictive approach for coupling of daunomycin to monoclonal antibodies. Hudecz F; Ross H; Price MR; Baldwin RW Bioconjug Chem; 1990; 1(3):197-204. PubMed ID: 2096913 [TBL] [Abstract][Full Text] [Related]
2. Preparation of four daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumour activity. Gallego J; Price MR; Baldwin RW Int J Cancer; 1984 Jun; 33(6):737-44. PubMed ID: 6376376 [TBL] [Abstract][Full Text] [Related]
3. The use of daunomycin-antibody immunoconjugates in managing soft tissue sarcomas: nude mouse xenograft model. Stastny JJ; Das Gupta TK Cancer Res; 1993 Dec; 53(23):5740-4. PubMed ID: 8242630 [TBL] [Abstract][Full Text] [Related]
4. Immunotargeting of daunomycin to localized and metastatic human colon adenocarcinoma in athymic mice. Hurwitz E; Adler R; Shouval D; Takahashi H; Wands JR; Sela M Cancer Immunol Immunother; 1992; 35(3):186-92. PubMed ID: 1638555 [TBL] [Abstract][Full Text] [Related]
5. Tumor reactive cis-aconitylated monoclonal antibodies coupled to daunorubicin through a peptide spacer are unable to kill tumor cells. Law KL; Studtmann KE; Carlson RE; Swanson TA; Buirge AW; Ahmad A Anticancer Res; 1990; 10(3):845-52. PubMed ID: 2369098 [TBL] [Abstract][Full Text] [Related]
6. Isomer-dependent daunomycin release and in vitro antitumour effect of cis-aconityl-daunomycin. Reményi J; Balázs B; Tóth S; Falus A; Tóth G; Hudecz F Biochem Biophys Res Commun; 2003 Apr; 303(2):556-61. PubMed ID: 12659854 [TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor activity of daunomycin conjugated with antigastric cancer monoclonal antibody MGb2. Li S; Zhang XY; Qiao TD; Chen XT; Zhang SY; Chen LJ Oncol Res; 1992; 4(11-12):447-53. PubMed ID: 1299375 [TBL] [Abstract][Full Text] [Related]
8. Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates. Dillman RO; Johnson DE; Ogden J; Beidler D Mol Biother; 1989; 1(5):250-5. PubMed ID: 2515870 [TBL] [Abstract][Full Text] [Related]
9. Abrogation of antibody responses in rats to murine monoclonal antibody 791T/36 by treatment with daunomycin-cis-aconityl-791T/36 conjugates. Durrant LG; Robins RA; Marksman RA; Garnett MC; Ogunmuyiwa Y; Baldwin RW Cancer Immunol Immunother; 1989; 28(1):37-42. PubMed ID: 2783300 [TBL] [Abstract][Full Text] [Related]
10. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug. Dillman RO; Johnson DE; Shawler DL; Koziol JA Cancer Res; 1988 Nov; 48(21):6097-102. PubMed ID: 3262420 [TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods. Sinkule JA; Rosen ST; Radosevich JA Tumour Biol; 1991; 12(4):198-206. PubMed ID: 1651554 [TBL] [Abstract][Full Text] [Related]
12. Modification of monoclonal and polyclonal IgG with palladium (II) coproporphyrin I: stimulatory and inhibitory functional effects induced by two different methods. Martsev SP; Preygerzon VA; Mel'nikova YI; Kravchuk ZI; Ponomarev GV; Lunev VE; Savitsky AP J Immunol Methods; 1995 Oct; 186(2):293-304. PubMed ID: 7594629 [TBL] [Abstract][Full Text] [Related]
13. Daunorubicin coupled to monoclonal antibodies via a cis-aconitic anhydride linker: biochemical and cytotoxic properties revisited. Ahmad A; Law KL; Young B; Telander MW; Ogden JR; Leung K Anticancer Res; 1990; 10(3):837-43. PubMed ID: 2369097 [TBL] [Abstract][Full Text] [Related]
14. Profiling antibody drug conjugate positional isomers: a system-of-equations approach. Le LN; Moore JM; Ouyang J; Chen X; Nguyen MD; Galush WJ Anal Chem; 2012 Sep; 84(17):7479-86. PubMed ID: 22913809 [TBL] [Abstract][Full Text] [Related]
15. Cytotoxic activity of daunorubicin or vindesin conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells. Aboud-Pirak E; Lesur B; Rao KS; Baurain R; Trouet A; Schneider YJ Biochem Pharmacol; 1989 Feb; 38(4):641-8. PubMed ID: 2917019 [TBL] [Abstract][Full Text] [Related]
16. Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. Lazar AC; Wang L; Blättler WA; Amphlett G; Lambert JM; Zhang W Rapid Commun Mass Spectrom; 2005; 19(13):1806-14. PubMed ID: 15945030 [TBL] [Abstract][Full Text] [Related]
17. A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid derivative as intermediate drug carrier. An anti-alpha-fetoprotein antibody-daunomycin conjugate. Kato Y; Umemoto N; Kayama Y; Fukushima H; Takeda Y; Hara T; Tsukada Y J Med Chem; 1984 Dec; 27(12):1602-7. PubMed ID: 6209394 [TBL] [Abstract][Full Text] [Related]
18. New daunomycin-oligoarginine conjugates: synthesis, characterization, and effect on human leukemia and human hepatoma cells. Miklán Z; Orbán E; Csík G; Schlosser G; Magyar A; Hudecz F Biopolymers; 2009; 92(6):489-501. PubMed ID: 19521976 [TBL] [Abstract][Full Text] [Related]